Copy
View this email in your browser

Lancet Commission on Essential Medicines Policies

 

Welcome to the September 2016 newsletter of the Lancet Commission on Essential Medicines Policies


This is the current issue of the Lancet Commission on Essential Medicines Policies Newsletter. Please check our website for more details on our work: http://www.bu.edu/lancet-commission-essential-medicines-policies/
 
Recent Updates: 

United Nations High Level Panel Report on Access to Medicines is now available
On September 14 the United Nations High Level Panel published its Report on Access to Medicines. It is publicly available at: http://www.unsgaccessmeds.org/final-report/. The 70-page report (including a number of Annexes) stresses that the development of new technologies, including medicines, offers enormous potential to improve health, while their costs put a strain on all countries. 

The 15-member High Level Panel on Access to Medicines was created by the Secretary General of the UN, Ban Ki Moon, in November 2015. Its mandate was to propose solutions for addressing the incoherencies among international human rights, trade, intellectual property rights and public health objectives. 

Relationship of the UN High Level Panel to the Lancet Commission on Essential Medicines
The UN High Level Panel’s focused specifically on innovation, mainly research and development of pharmaceuticals and related technologies. Members of the Lancet Commission made contributions on these topics. The Lancet Commission looked at a broader set of related issues; the development of new essential medicines is one of five focus areas. 

Both reports agree on several aspects related to R&D, such as:
  • Increasing investments in R&D to address current treatment gaps, particularly for diseases that disproportionally affect poor populations 
  • Making full use of TRIPS flexibilities to promote access to essential medicines whenever necessary
  • Implementing robust accountability frameworks to hold all stakeholders responsible for the impact of their actions on access to medicines and health technologies.
Launch of LCEMP Final Report
The final report will be published on November 8, 2016

For more information on the upcoming launch event in London and subsequent dissemination events around the world please go to: http://www.thelancet.com/pb/assets/raw/Lancet/homepage/announcements/Essential_Medicines_Policies_launch.pdf
Recent Publications: Useful Publications on Antimicrobial Resistance
Upcoming Events and News relevant to Essential Medicines Policies: 

           Stay tuned for the October Newsletter with more information.

       Several sessions related to medicines policies, including:
  • November 16, 6:45-8:15 (PST): Rigorous evaluation of industry-led Access to Medicines programs in low- and middle-income countries [Satellite Session, Pan Pacific Hotel at Conference Venue]
  • November 18, 8:30-10:00 (PST): Policy-maker–researcher collaborations in improving access to medicines: getting the prescription right 
  • November 18, 10:30-12:00 (PST): Thematic Working Group on Medicines: Access to novel, high-cost cancer medicines towards a more holistic, ethical and practical framework for health systems decisions. 
Spotlight: 

Lancet EMP Commissioner: Dennis Ross-Degnan

Email: dennis_ross-degnan@hms.harvard.edu

Throughout his career, Dennis Ross-Degnan’s main academic focus has been developing evidence-based strategies for improving use of medicines. Dr. Ross-Degnan is Associate Professor at the Department of Population Medicine at Harvard Medical School and Director of Research at Harvard Pilgrim Health Care Institute. For over thirty years, Dr. Ross-Degnan has focused on improving health systems both in the US and in low- and middle-income countries, addressing behavioral and systems factors that determine use of medicines, impacts of health and pharmaceutical policies on utilization and clinical outcomes, and appropriate methods for health and pharmaceutical systems research. 

Dr. Ross-Degnan has served as a lead or senior investigator on many domestic and international research studies to evaluate health systems initiatives to improve quality and outcomes of care, including studies examining: interactive education; pharmaceutical and insurance benefit design; systems interventions to improve ARV adherence; high deductible health plans for patients with chronic illness; using hospital-based community health workers to reduce hospital readmissions; electronic and telephone outreach to health providers and patients to improve utilization; and systems interventions in low resource settings to promote appropriate prescribing and use of medicines. 

Dr. Ross-Degnan collaborates extensively with members of the International Network for Rational Use of Drugs (INRUD), an interdisciplinary network of academics, health managers, and policymakers that he co-founded in 1990. With INRUD colleagues, he has developed accessible, robust, globally accepted methods to: measure medicines use, prices, and intervention effects; systematically evaluate evidence; disseminate results; and build human capacity. Dr. Ross-Degnan and colleagues developed a two-week INRUD-WHO Promoting Rational Drug Use Course, a modular, problem-oriented, interactive course to introduce researchers and policy makers to concepts in improving medicines use, which was offered annually for over 20 years in Africa and Asia. He chaired the Scientific Program Committees for the first two International Conferences on Improving Use of Medicines (ICIUM 1997 and 2004) and served as senior member for the Scientific Program Committee in ICIUM 2011. 

He has also collaborated extensively with WHO and other international organizations on global issues in pharmaceutical policy, serving as co-Director of a WHO Collaborating Center on Pharmaceutical Policy from 2004 to 2013.  

Dr. Ross-Degnan holds a doctorate in health policy and management from the Harvard T.H. Chan School of Public Health. Thus far, Dr. Ross-Degnan has mentored more than 70 PhD students and post-doctoral fellows from 22 countries. He received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School and the Klaus Peter International Teaching Award for distinction in international medical education and mentoring from Harvard Medical International and Harvard Medical School. 

Dr. Ross-Degnan has over 200 publications listed on PubMed. Some recent publications of note include:
1.    Ross-Degnan D, Vialle-Valentin C, Briggs J. Improving Medicines Access and Use for Child Health: A Guide to Developing Interventions. US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health: 2015.
2.    Wagner AK, Wirtz VJ, Bigdeli M, Ho CWL, Ross-Degnan D. The role of medicines in achieving universal health coverage. In Bigdeli M, Peters DH, Wagner AK (Eds.) Medicines in health systems: advancing access, affordability and appropriate use. Geneva; World Health Organization: 2014.
3.    Chalker JC, Vialle-Valentin C, Liana J, Mbwasi R, Semali IA, Kihiyo B, Shekalaghe E, Dillip A, Kimatta S, Valimba R, Embrey M, Lieber R, Rutta E, Johnson K, Ross-Degnan D.  What roles do accredited drug dispensing outlets in Tanzania play in facilitating access to antimicrobials? Results of a multi-method analysis. Antimicrob Resist Infect Control. 2015 Aug 20;4:33. 
4.    Vialle-Valentin C, Brian Serumaga B, Wagner AK, Ross-Degnan D.  Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries.  Health Policy and Planning 2015 30: 1044-1052.
5.    Balaban RB, Galbraith AA, Burns ME, Vialle-Valentin CE, Larochelle MR, Ross-Degnan D. A Patient Navigator intervention to reduce hospital readmissions among high-risk safety-net patients: A randomized controlled trial. J Gen Intern Med. 2015 Jul;30(7):907-15.

 

Twitter
Website
September, 2016
Copyright © 2016 Lancet Commission on Essential Medicines Policies, All rights reserved.
You are receiving this email because you have expressed interest in the commission, have been involved in the commission process or were recommended by a colleague. You can unsubscribe by clicking the link at the bottom of the email. We encourage you to pass this email along to anyone who might be interested. Please visit our website at http://www.bu.edu/lcemp



unsubscribe from this list    update subscription preferences 

 






This email was sent to vwirtz@bu.edu
why did I get this?    unsubscribe from this list    update subscription preferences
Lancet EMP · 801 Massachusetts Avenue · Boston, MA 02118 · USA

Email Marketing Powered by Mailchimp